CN-121971479-A - Application of astragalus polysaccharide in preparation of NK cell activating products

Abstract

The invention relates to the technical field of biological medicine and tumor immunotherapy, in particular to application of astragalus polysaccharide in preparation of an NK cell activating product. The invention provides astragalus polysaccharide for activating NK cells and enhancing tumor killing function, and the effective concentration, action time and functional phenotype change of astragalus polysaccharide are clear, so that experimental basis is provided for application of astragalus polysaccharide in tumor immunotherapy, immune enhancement preparation and functional products.

Inventors

• SUN HE
• MA XIAOHUI
• ZHANG ZUOLI
• LI QINGCUI
• ZHOU SHENGBIN

Assignees

• 天士力医药集团股份有限公司

Dates

Publication Date

20260505

Application Date

20260404

Claims (10)

1. 1. The application of astragalus polysaccharide in preparing NK cell activating product.
2. 2. The use according to claim 1, wherein the astragalus polysaccharide activates NK cells at a concentration of 5-50 μg/mL.
3. 3. The use according to claim 1 or 2, wherein the astragalus polysaccharide is used at a concentration of 20 μg/mL for activating NK cells.
4. 4. The use according to claim 1, wherein the astragalus polysaccharide activates NK cells for 24-72 hours.
5. 5. The use according to claim 1 or 4, wherein the astragalus polysaccharide activates NK cells for 48 hours.
6. 6. The use according to claim 1, wherein the astragalus polysaccharide upregulates the expression of NK cell activation related markers including CD69, NKG2D and DNAM-1.
7. 7. The use according to claim 1, wherein the astragalus polysaccharide promotes NK cells to secrete effectors including IFN- γ, TNF- α and granzyme B.
8. 8. Application of astragalus polysaccharide in preparing products for activating NK cells and enhancing tumor cell killing function is provided.
9. 9. The use of claim 8, wherein the tumor cells comprise K562 tumor cells.
10. 10. The use according to claim 1 or 8, wherein the NK cells comprise a human NK92 cell line.

Description

Application of astragalus polysaccharide in preparation of NK cell activating products Technical Field The invention relates to the technical field of biological medicine and tumor immunotherapy, in particular to application of astragalus polysaccharide in preparation of an NK cell activating product. Background Natural killer cells (Natural KILLER CELLS, NK cells) are an important component of the innate immune system, playing a key role in anti-tumor immunity. Unlike T cells, NK cells can directly recognize and kill tumor cells without antigen presentation, and have the advantages of fast onset of action, no MHC restriction, etc. However, in tumor microenvironments, NK cells are often in a functionally inhibited or poorly responsive state, with significantly reduced activation and killing capabilities, limiting their clinical utility. The current strategies for activating NK cells mainly comprise cytokine stimulation (such as IL-2 and IL-15) or genetic engineering modification, but the methods have the problems of high cost, large side effect or safety risk and the like. Therefore, the natural immune regulator with safety, effectiveness and definite source is developed, is used for enhancing the activity of NK cells, and has important scientific significance and application value. Astragalus is a traditional Chinese medicinal material, astragalus polysaccharide is one of main active ingredients of the astragalus polysaccharide, and whether the astragalus polysaccharide can directly activate NK cells, enhance the tumor killing function and the optimal action condition of the astragalus polysaccharide is not supported by systematic and clear experimental data at present. Disclosure of Invention In order to solve the problems, the invention provides application of astragalus polysaccharide in preparing an NK cell activating product, provides the astragalus polysaccharide for activating NK cells and enhancing tumor killing function, and defines effective concentration, action time and functional phenotype change of the astragalus polysaccharide, thereby providing experimental basis for application of the astragalus polysaccharide in tumor immunotherapy, immune enhancing preparation and functional products. In order to achieve the above object, the present invention provides the following technical solutions: the invention provides application of astragalus polysaccharide in preparation of an NK cell activating product. Preferably, the use concentration of the astragalus polysaccharide activated NK cells is 5-50 mug/mL. Preferably, the astragalus polysaccharide activates NK cells at a concentration of 20 μg/mL. Preferably, the time for activating NK cells by the astragalus polysaccharide is 24-72 h. Preferably, the astragalus polysaccharide activates NK cells for 48 hours. Preferably, the astragalus polysaccharide upregulates the expression of NK cell activation related markers including CD69, NKG2D and DNAM-1. Preferably, the astragalus polysaccharide promotes NK cells to secrete effectors including IFN-gamma, TNF-alpha and granzyme B. The invention also provides application of the astragalus polysaccharide in preparing products for activating NK cells and enhancing tumor cell killing function. Preferably, the tumor cells comprise K562 tumor cells. Preferably, the NK cells comprise a human NK92 cell line. The invention has the beneficial effects that: 1. The first system defines the optimal condition (20 mug/mL, 48 h) for directly activating NK cells by astragalus polysaccharide; 2. The role is demonstrated in several aspects from phenotype (flow), protein (WB), transcription (qPCR) and function (killing experiments); 3. Obviously enhancing the tumor killing capability of NK cells and having potential application value in tumor immunotherapy; 4. The astragalus polysaccharide is natural in source and high in safety, and is suitable for further development into immunoregulation products or combined treatment strategies. Drawings In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings that are required to be used in the embodiments will be briefly described below. FIG. 1 shows the promoting effect of astragalus polysaccharide on NK92 cell activation marker expression (corresponding to example 1), wherein NK92 cells are treated by APS at different concentrations, (A-B) a representative flow chart for NKG2D expression detection and statistical results, (C-D) a representative flow chart for CD96 expression detection and statistical results, and (E) DNAM-1 expression level statistical results; FIG. 2 shows the effect of astragalus polysaccharides on NK92 cell NKG2D protein expression (corresponding examples 2, 3), (A-B) different concentrations of APS treatment of NK92 cell NKG2D protein expression level and statistics, and (C-D) APS treatment of different times of NK92 cell NKG2D protein expression level and statistics; FIG. 3 shows the